Literature DB >> 34326068

TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes.

Maria J Redondo1, Megan V Warnock2, Ingrid M Libman3, Laura E Bocchino2,4, David Cuthbertson2, Susan Geyer2,5, Alberto Pugliese6, Andrea K Steck7, Carmella Evans-Molina8, Dorothy Becker3, Jay M Sosenko9, Fida Bacha10,11.   

Abstract

OBJECTIVE: We aimed to test whether type 2 diabetes (T2D)-associated TCF7L2 genetic variants affect insulin sensitivity or secretion in autoantibody-positive relatives at risk for type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: We studied autoantibody-positive TrialNet Pathway to Prevention study participants (N = 1,061) (mean age 16.3 years) with TCF7L2 single nucleotide polymorphism (SNP) information and baseline oral glucose tolerance test (OGTT) to calculate indices of insulin sensitivity and secretion. With Bonferroni correction for multiple comparisons, P values < 0.0086 were considered statistically significant.
RESULTS: None, one, and two T2D-linked TCF7L2 alleles were present in 48.1%, 43.9%, and 8.0% of the participants, respectively. Insulin sensitivity (as reflected by 1/fasting insulin [1/IF]) decreased with increasing BMI z score and was lower in Hispanics. Insulin secretion (as measured by 30-min C-peptide index) positively correlated with age and BMI z score. Oral disposition index was negatively correlated with age, BMI z score, and Hispanic ethnicity. None of the indices were associated with TCF7L2 SNPs. In multivariable analysis models with age, BMI z score, ethnicity, sex, and TCF7L2 alleles as independent variables, C-peptide index increased with age, while BMI z score was associated with higher insulin secretion (C-peptide index), lower insulin sensitivity (1/IF), and lower disposition index; there was no significant effect of TCF7L2 SNPs on any of these indices. When restricting the analyses to participants with a normal OGTT (n = 743; 70%), the results were similar.
CONCLUSIONS: In nondiabetic autoantibody-positive individuals, TCF7L2 SNPs were not related to insulin sensitivity or secretion indices after accounting for BMI z score, age, sex, and ethnicity.
© 2021 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34326068      PMCID: PMC8740915          DOI: 10.2337/dc21-0531

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  35 in total

1.  Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes?

Authors:  Ingrid M Libman; Dorothy J Becker
Journal:  Pediatr Diabetes       Date:  2003-06       Impact factor: 4.866

2.  Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents.

Authors:  Neslihan Gungor; Rola Saad; Janine Janosky; Silva Arslanian
Journal:  J Pediatr       Date:  2004-01       Impact factor: 4.406

3.  Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

Authors:  Valeriya Lyssenko; Roberto Lupi; Piero Marchetti; Silvia Del Guerra; Marju Orho-Melander; Peter Almgren; Marketa Sjögren; Charlotte Ling; Karl-Fredrik Eriksson; Asa-Linda Lethagen; Rita Mancarella; Göran Berglund; Tiinamaija Tuomi; Peter Nilsson; Stefano Del Prato; Leif Groop
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

Authors:  Carla J Greenbaum; Ronald L Prigeon; David A D'Alessio
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

5.  C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.

Authors:  Magdalena M Bogun; Brian N Bundy; Robin S Goland; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2020-05-26       Impact factor: 19.112

6.  Variants and haplotypes of TCF7L2 are associated with β-cell function in patients with newly diagnosed type 2 diabetes: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 1.

Authors:  S Bonetti; M Trombetta; G Malerba; L Boselli; E Trabetti; M Muggeo; V Stoico; C Negri; P F Pignatti; E Bonora; R C Bonadonna
Journal:  J Clin Endocrinol Metab       Date:  2010-12-15       Impact factor: 5.958

7.  Type 1 Diabetes TrialNet--an international collaborative clinical trials network.

Authors:  Jay S Skyler; Carla J Greenbaum; John M Lachin; Ellen Leschek; Lisa Rafkin-Mervis; Peter Savage; Lisa Spain
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  A Reduced Incretin Effect Mediated by the rs7903146 Variant in the TCF7L2 Gene Is an Early Marker of β-Cell Dysfunction in Obese Youth.

Authors:  Alfonso Galderisi; Domenico Tricò; Bridget Pierpont; Veronika Shabanova; Stephanie Samuels; Chiara Dalla Man; Brittany Galuppo; Nicola Santoro; Sonia Caprio
Journal:  Diabetes Care       Date:  2020-08-11       Impact factor: 19.112

9.  Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci.

Authors:  Richa Saxena; Clara C Elbers; Yiran Guo; Inga Peter; Tom R Gaunt; Jessica L Mega; Matthew B Lanktree; Archana Tare; Berta Almoguera Castillo; Yun R Li; Toby Johnson; Marcel Bruinenberg; Diane Gilbert-Diamond; Ramakrishnan Rajagopalan; Benjamin F Voight; Ashok Balasubramanyam; John Barnard; Florianne Bauer; Jens Baumert; Tushar Bhangale; Bernhard O Böhm; Peter S Braund; Paul R Burton; Hareesh R Chandrupatla; Robert Clarke; Rhonda M Cooper-DeHoff; Errol D Crook; George Davey-Smith; Ian N Day; Anthonius de Boer; Mark C H de Groot; Fotios Drenos; Jane Ferguson; Caroline S Fox; Clement E Furlong; Quince Gibson; Christian Gieger; Lisa A Gilhuijs-Pederson; Joseph T Glessner; Anuj Goel; Yan Gong; Struan F A Grant; Diederick E Grobbee; Claire Hastie; Steve E Humphries; Cecilia E Kim; Mika Kivimaki; Marcus Kleber; Christa Meisinger; Meena Kumari; Taimour Y Langaee; Debbie A Lawlor; Mingyao Li; Maximilian T Lobmeyer; Anke-Hilse Maitland-van der Zee; Matthijs F L Meijs; Cliona M Molony; David A Morrow; Gurunathan Murugesan; Solomon K Musani; Christopher P Nelson; Stephen J Newhouse; Jeffery R O'Connell; Sandosh Padmanabhan; Jutta Palmen; Sanjey R Patel; Carl J Pepine; Mary Pettinger; Thomas S Price; Suzanne Rafelt; Jane Ranchalis; Asif Rasheed; Elisabeth Rosenthal; Ingo Ruczinski; Sonia Shah; Haiqing Shen; Günther Silbernagel; Erin N Smith; Annemieke W M Spijkerman; Alice Stanton; Michael W Steffes; Barbara Thorand; Mieke Trip; Pim van der Harst; Daphne L van der A; Erik P A van Iperen; Jessica van Setten; Jana V van Vliet-Ostaptchouk; Niek Verweij; Bruce H R Wolffenbuttel; Taylor Young; M Hadi Zafarmand; Joseph M Zmuda; Michael Boehnke; David Altshuler; Mark McCarthy; W H Linda Kao; James S Pankow; Thomas P Cappola; Peter Sever; Neil Poulter; Mark Caulfield; Anna Dominiczak; Denis C Shields; Deepak L Bhatt; Deepak Bhatt; Li Zhang; Sean P Curtis; John Danesh; Juan P Casas; Yvonne T van der Schouw; N Charlotte Onland-Moret; Pieter A Doevendans; Gerald W Dorn; Martin Farrall; Garret A FitzGerald; Anders Hamsten; Robert Hegele; Aroon D Hingorani; Marten H Hofker; Gordon S Huggins; Thomas Illig; Gail P Jarvik; Julie A Johnson; Olaf H Klungel; William C Knowler; Wolfgang Koenig; Winfried März; James B Meigs; Olle Melander; Patricia B Munroe; Braxton D Mitchell; Susan J Bielinski; Daniel J Rader; Muredach P Reilly; Stephen S Rich; Jerome I Rotter; Danish Saleheen; Nilesh J Samani; Eric E Schadt; Alan R Shuldiner; Roy Silverstein; Kandice Kottke-Marchant; Philippa J Talmud; Hugh Watkins; Folkert W Asselbergs; Folkert Asselbergs; Paul I W de Bakker; Jeanne McCaffery; Cisca Wijmenga; Marc S Sabatine; James G Wilson; Alex Reiner; Donald W Bowden; Hakon Hakonarson; David S Siscovick; Brendan J Keating
Journal:  Am J Hum Genet       Date:  2012-02-09       Impact factor: 11.025

10.  TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

Authors:  Dennis T Villareal; Heather Robertson; Graeme I Bell; Bruce W Patterson; Hung Tran; Burton Wice; Kenneth S Polonsky
Journal:  Diabetes       Date:  2009-11-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.